LYRA

Lyra Therapeutics, Inc.$0.55+0.00 (—)

Prev Close$1.32·MCap$2.3M·P/E—·Vol—·Yield—

▲

Buys (12M)

$0.00

▼

Sells (12M)

$36.7K

◆

Net Activity

Net Seller

$36.7K

●

Active Insiders

last 12 mo

Over the past 12 months, insider activity at Lyra Therapeutics, Inc. (LYRA) has been exclusively selling, with 0 insider purchases totaling $0.00 and 6 insider sales totaling $36.7K. The most recent insider transaction was by Cavalier Jason (officer: Chief Financial Officer), who sold $2.6K worth of shares on Jan 8, 2026. Lyra Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.3M.

LYRA Insider Trading Activity

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Jan 8, 2026	Cavalier Jason	officer: Chief Financial Officer	Sell	769	$3.36	$2.6K	518,547
Jan 8, 2026	Palasis Maria	director, officer: President & CEO	Sell	1,702	$3.36	$5.7K	1,096,733
Jan 6, 2026	Palasis Maria	President & CEO	Sell	1,702	$3.36	$5.7K	0
Jan 6, 2026	Cavalier Jason	Chief Financial Officer	Sell	769	$3.36	$2.6K	0
Jul 10, 2025	Cavalier Jason	Chief Financial Officer	Sell	684	$8.91	$6.1K	0
Jul 10, 2025	Palasis Maria	President & CEO	Sell	1,565	$8.91	$13.9K	0
Nov 13, 2023	Waksal Harlan	Executive Chair	Buy	25,000	$2.96	$74.1K1.4% OS	261,966
Jun 2, 2023	NBVM GP, LLC	10% Owner	Buy	2,708,124	$1.66	$4.50M152.6% OS	2,521,745
Jun 2, 2023	PERCEPTIVE ADVISORS LLC	Director	Buy	3,610,832	$2.49	$9.00M203.4% OS	11,469,117+46%
Jun 13, 2022	MERRIFIELD C ANN	Director	Buy	4,000	$5.05	$20.2K	11,328+55%
May 17, 2022	MERRIFIELD C ANN	Director	Buy	3,828	$4.83	$18.5K	7,328+109%
Apr 14, 2022	ANDERSON EDWARD T	Director	Buy	118,483	$4.22	$500.0K6.7% OS	118,483
Apr 14, 2022	NBVM GP, LLC	10% Owner	Buy	2,369,667	$4.22	$10.00M133.5% OS	1,855,443
Apr 14, 2022	PERCEPTIVE ADVISORS LLC	Director	Buy	5,924,170	$4.22	$25.00M333.8% OS	7,858,285+306%
Apr 13, 2022	Waksal Harlan	Executive Chair	Buy	236,966	$4.22	$1000.0K13.4% OS	236,966
Jun 22, 2021	MERRIFIELD C ANN	Director	Buy	3,500	$8.97	$31.4K	3,500

LYRA Insider Buying Activity

The following table shows recent insider purchases of Lyra Therapeutics, Inc. (LYRA) stock reported via SEC Form 4 filings.

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Nov 13, 2023	Waksal Harlan	Executive Chair	Buy	25,000	$2.96	$74.1K1.4% OS	261,966
Jun 2, 2023	NBVM GP, LLC	10% Owner	Buy	2,708,124	$1.66	$4.50M152.6% OS	2,521,745
Jun 2, 2023	PERCEPTIVE ADVISORS LLC	Director	Buy	3,610,832	$2.49	$9.00M203.4% OS	11,469,117+46%
Jun 13, 2022	MERRIFIELD C ANN	Director	Buy	4,000	$5.05	$20.2K	11,328+55%
May 17, 2022	MERRIFIELD C ANN	Director	Buy	3,828	$4.83	$18.5K	7,328+109%
Apr 14, 2022	ANDERSON EDWARD T	Director	Buy	118,483	$4.22	$500.0K6.7% OS	118,483
Apr 14, 2022	NBVM GP, LLC	10% Owner	Buy	2,369,667	$4.22	$10.00M133.5% OS	1,855,443
Apr 14, 2022	PERCEPTIVE ADVISORS LLC	Director	Buy	5,924,170	$4.22	$25.00M333.8% OS	7,858,285+306%
Apr 13, 2022	Waksal Harlan	Executive Chair	Buy	236,966	$4.22	$1000.0K13.4% OS	236,966
Jun 22, 2021	MERRIFIELD C ANN	Director	Buy	3,500	$8.97	$31.4K	3,500

LYRA Insider Selling Activity

The following table shows recent insider sales of Lyra Therapeutics, Inc. (LYRA) stock reported via SEC Form 4 filings.

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Jan 8, 2026	Cavalier Jason	officer: Chief Financial Officer	Sell	769	$3.36	$2.6K	518,547
Jan 8, 2026	Palasis Maria	director, officer: President & CEO	Sell	1,702	$3.36	$5.7K	1,096,733
Jan 6, 2026	Palasis Maria	President & CEO	Sell	1,702	$3.36	$5.7K	0
Jan 6, 2026	Cavalier Jason	Chief Financial Officer	Sell	769	$3.36	$2.6K	0
Jul 10, 2025	Cavalier Jason	Chief Financial Officer	Sell	684	$8.91	$6.1K	0
Jul 10, 2025	Palasis Maria	President & CEO	Sell	1,565	$8.91	$13.9K	0